跳转至内容
Merck

E9156

Sigma-Aldrich

Encainide 盐酸盐

≥98% (HPLC), powder

别名:

(+/-)-4-Methoxy-N-[2-[2-(1-methyl-2-piperidinyl)ethyl]phenyl]benzamide 盐酸盐, MJ-9067

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C22H28N2O2 · HCl
CAS号:
分子量:
388.93
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77

方案

≥98% (HPLC)

表单

powder

溶解性

H2O: >25 mg/mL

创始人

Bristol-Myers Squibb

储存温度

2-8°C

SMILES字符串

Cl.COc1ccc(cc1)C(=O)Nc2ccccc2CCC3CCCCN3C

InChI

1S/C22H28N2O2.ClH/c1-24-16-6-5-8-19(24)13-10-17-7-3-4-9-21(17)23-22(25)18-11-14-20(26-2)15-12-18;/h3-4,7,9,11-12,14-15,19H,5-6,8,10,13,16H2,1-2H3,(H,23,25);1H

InChI key

OJIIZIWOLTYOBS-UHFFFAOYSA-N

生化/生理作用

Encainide hydrochloride is a sodium channel blocker and class Ic antiarrhythmic.
Encainide hydrochloride is a sodium channel blocker and class Ic antiarrhythmic. Encainide is a non-chiral antiarrhythmic and benzanilide derivative.

特点和优势

This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形图

Skull and crossbones

警示用语:

Danger

危险分类

Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

靶器官

Respiratory system

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

D Obias-Manno et al.
Annals of epidemiology, 6(2), 93-101 (1996-03-01)
Patient adherence to therapy is essential to assess treatment efficacy, particularly in clinical trials. Active treatment usually is expected to benefit patients. The healthy adherer effect, the association or greater adherence to all health-promoting behaviors, including medication and overall concern
J E Tisdale et al.
Journal of clinical pharmacology, 33(7), 623-630 (1993-07-01)
The efficacy of class 1C antiarrhythmic agents was determined in 36 patients with inducible sustained monomorphic ventricular tachycardia during baseline electrophysiology study (EPS), who continued to have inducible monomorphic ventricular tachycardia during EPS on class 1A antiarrhythmic therapy. Of 12
H J Duff et al.
The Journal of pharmacology and experimental therapeutics, 274(1), 508-515 (1995-07-01)
Encainide treatment in patients after myocardial infarction is associated with increased risk of sudden cardiac death. This may relate to drug-induced changes in the electrophysiologic milieu, thus predisposing the patient to sustained ventricular tachyarrhythmias. The goals of this study were
A E Epstein et al.
JAMA, 270(20), 2451-2455 (1993-11-24)
To test the hypothesis that in survivors of myocardial infarction, the suppression of ventricular premature depolarizations improves survival free of cardiac arrest and arrhythmic death. International, prospective, multicenter, randomized, placebo-controlled trial. University and community hospitals. A total of 3549 patients
S Goldstein et al.
Circulation, 91(1), 79-83 (1995-01-01)
We tested the hypothesis that patients whose ventricular arrhythmias are easy to suppress have a lower rate of arrhythmic death, defined as arrhythmic death and nonfatal cardiac arrest, the primary end point in the Cardiac Arrhythmia Suppression Trials (CAST-I and

商品

电压门控钠通道存在于大多数可兴奋细胞膜中,在产生动作电位方面起着重要作用。

Voltage-gated sodium channels are present in most excitable cell membranes and play an important role in generating action potentials.

Questions

Reviews

No rating value

Active Filters

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门